VIDEO: ‘Big year’ for IL-23 inhibitors in trials for ulcerative colitis
Click Here to Manage Email Alerts
In this Healio video, Uma Mahadevan, MD, director of the Colitis and Crohn’s Disease Center at the University of California, San Francisco, discusses new study results assessing the use of interleukin-23 inhibitors in ulcerative colitis.
“This was a big year for the IL-23s, with respect to ulcerative colitis,” Mahadevan told Healio.
Results from the QUASAR maintenance study, which were presented in May at Digestive Disease Week, found that maintenance therapy with Tremfya (guselkumab, Janssen) was more effective than placebo at 44 weeks among patients with moderate to severe UC, she noted.
Mahadevan also highlighted findings from the COMMAND maintenance study, which found that Skyrizi (risankizumab, AbbVie) was superior to placebo in achieving clinical remission in UC.
According to Mahadevan, Omvoh (mirikizumab, Lilly) is currently the only IL-23 approved for UC in the United States, and Stelara (ustekinumab, Janssen), an IL-12/23, is approved for both Crohn’s and UC.
“So, it’ll be exciting to have these new agents out in this area,” she said.
References:
- Rubin DT, et al. The efficacy and safety of guselkumab as maintenance therapy in patients with moderately to severe active ulcerative colitis: Results from the phase 3 QUASAR maintenance study. Presented at: Digestive Disease Week; May 18-21, 2024; Washington (hybrid).
- Schreiber S, et al. Risankizumab maintenance therapy in patients with moderately to severely active ulcerative colitis: Efficacy and safety in the randomized phase 3 COMMAND study. Presented at: Digestive Disease Week; May 18-21, 2024; Washington (hybrid).
Collapse
Healio Interviews
Click Here to Manage Email Alerts